Register

Rheumatology

Immunotherapy   

Questions discussed in this category

Would you stop azathioprine in a patient with ANCA vasculitis who has been in long term remission on azathioprine, but has a new diagnosis of lung cancer requiring initiation of immunotherapy?
2 Answers available
Do you use immune checkpoint inhibitors in NSCLC patients with pre-existing, well-controlled autoimmune disease?
Does the type of autoimmune disease (ex IBD, rheumatoid arthritis, interstitial lung disease) matter?
2 Answers available
How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?
1 Answer available
Is it safe to treat checkpoint inhibitor-induced arthritis with methotrexate or biologics?
1 Answer available
Would you consider antiphospholipid syndrome to be a contraindication for checkpoint inhibitor immunotherapy?
2 Answers available
How would you treat a patient with active lupus nephritis (class 3/4) who requires PD-1 immunotherapy for refractory metastatic renal cell carcinoma?
2 Answers available
How do you manage steroid-refractory immune checkpoint inhibitor induced pneumonitis?
4 Answers available
What are your recommendations for a patient with metastatic non-mutated lung adenocarcinoma who previously had headaches responsive to prednisone but with negative temporal artery biopsy for GCA?
For medical oncologists, would you offer a PD-1/L1 inhibitor? For other subspecialties, how would you counsel the oncologist regarding the risk of usi...
1 Answer available
How do you approach the management of SSc-ILD in a patient on immune checkpoint therapy?
1 Answer available
Is your approach to managing immune related adverse events altered at all in light of COVID-19?
2 Answers available
How do you approach further treatment of patients who develop grade 2-3 immune colitis from nivolumab/ipilimumab prior to completion of the 4 ipilimumab doses?
Do you re-challenge with nivolumab alone, change from nivo 1/ipi 3 to nivo 3/ipi 1 upon re-challenge, or stop immunotherapy altogether if grade 3?&nbs...
1 Answer available
Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?
1 Answer available
Is there a period of time after which you would not resume ICI after a patient has had an irAE and required a prolonged steroid taper?
1 Answer available
Would the need for infliximab/MTX/nonsteroidals to control initial irAE affect your decision to rechallenge these patients with ICI?
1 Answer available


Papers discussed in this category

Nature reviews. Rheumatology, 2022 Oct 05
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases.
Oncoimmunology, 2023 Oct 30
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
J Immunother Cancer, 2019 Aug 22
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events.
Journal for immunotherapy of cancer, 2017-11-21
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Cancer management and research, 2017
Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.
Lancet Oncol., 2020 Mar 03
Risk of COVID-19 for patients with cancer.
Lancet, 2020 Feb 07
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.
Ann. Rheum. Dis., 2019 Sep 20
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.
J Immunother Cancer, 2021 Feb
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.
J Natl Compr Canc Netw,
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
Ann Oncol,
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J Immunother Cancer,
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
J Immunother Cancer,
Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis.
J Clin Oncol, 2021 Dec 20
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
J Natl Compr Canc Netw,
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
Melanoma research, 2017-04
Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.
Lung Cancer, 2021 Aug 03
Antiphospholipid syndrome-induced ischemic stroke following pembrolizumab: Case report and systematic review.
SAGE Open Med Case Rep, 2020 Nov 06
Severe mesenteric ischemia with multiple organ failure in a patient previously treated with a humanized monoclonal antibody against programmed death receptor-1 (pembrolizumab), a case of pembrolizumab associated catastrophic antiphospholipid syndrome?
Lancet Oncol, 2019 Jan
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015-05
Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
J Immunother Cancer, 2021 Jul
Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016 Jul 07
Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis.
Arthritis & rheumatology (Hoboken, N.J.), 2019 Oct 21
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
European journal of cancer (Oxford, England : 1990), 2023 Dec 28
Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG.
Arthritis and rheumatism, 2006 Mar
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Related Topics in Rheumatology

Copyright © 2024 theMednet
All Rights Reserved.